Neurology. 1991 Apr;41(4):533-9.

A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis.

Bornstein MB, Miller A, Slagle S, Weitzman M, Drexler E, Keilson M, Spada V, Weiss W, Appel S, Rolak L, et al.

Source

Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461.

Abstract

We found Cop 1 to be effective and relatively safe in a previous (exacerbating-remitting) clinical trial. This current trial involves 106 chronic-progressive patients. The major end point, confirmed progression of 1.0 or 1.5 units (depending on baseline disability) on the Kurtzke Expanded Disability Status Scale, was observed in nine (17.6%) treated and 14 (25.5%) control patients. The differences between the overall survival curves were not significant. Progression rates at 12 and 24 months were higher for the placebo group (p = 0.088) with 2-year probabilities of progressing of 20.4% for Cop 1 and 29.5% for placebo. We found a significant difference at 24 months between placebo and Cop 1 at one but not the other center. Two-year progression rates for two secondary end points, unconfirmed progression, and progression of 0.5 EDSS units, (p = 0.03) are significant.

PMID:: 2011253; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Ovid Technologies, Inc.

Medical

Multiple Sclerosis - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Review Mitoxantrone: a review of its use in multiple sclerosis. [CNS Drugs. 2004]
Review Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ, Figgitt DP. CNS Drugs. 2004; 18(6):379-96.
A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. [N Engl J Med. 1987]
A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis.
Bornstein MB, Miller A, Slagle S, Weitzman M, Crystal H, Drexler E, Keilson M, Merriam A, Wassertheil-Smoller S, Spada V. N Engl J Med. 1987 Aug 13; 317(7):408-14.
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. [Neurology. 1995]
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB. Neurology. 1995 Jul; 45(7):1268-76.
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) [Ann Neurol. 1996]
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)
Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, et al. Ann Neurol. 1996 Mar; 39(3):285-94.
Review Management of worsening multiple sclerosis with mitoxantrone: a review. [Clin Ther. 2006]
Review Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ. Clin Ther. 2006 Apr; 28(4):461-74.

See reviews... See all...

Cited by 12 PubMed Central articles

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. [Ther Adv Neurol Disord. 2011]
Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.
Boster A, Bartoszek MP, O'Connell C, Pitt D, Racke M. Ther Adv Neurol Disord. 2011 Sep; 4(5):319-32.
Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. [Mult Scler. 2010]
Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate.
Ford C, Goodman AD, Johnson K, Kachuck N, Lindsey JW, Lisak R, Luzzio C, Myers L, Panitch H, Preiningerova J, et al. Mult Scler. 2010 Mar; 16(3):342-50. Epub 2010 Jan 27.
Glatiramer acetate in the treatment of multiple sclerosis. [Neuropsychiatr Dis Treat. 2007]
Glatiramer acetate in the treatment of multiple sclerosis.
Tselis A, Khan O, Lisak RP. Neuropsychiatr Dis Treat. 2007 Apr; 3(2):259-67.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Recent activity

Clear Turn Off Turn On

A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1...
A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis.
Neurology. 1991 Apr ;41(4):533-9.

PubMed
Functional changes in microcirculation during hyperbaric and normobaric oxygen t...
Functional changes in microcirculation during hyperbaric and normobaric oxygen therapy.
Undersea Hyperb Med. 2009 Sep-Oct ;36(5):381-90.

PubMed
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II....
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.
Neurology. 1991 Apr ;41(4):479-86.

PubMed
The HLA-B*2705 peptidome.
The HLA-B*2705 peptidome.
Arthritis Rheum. 2010 Feb ;62(2):420-9.

PubMed
ADAM28 is a serological and histochemical marker for non-small-cell lung cancers...
ADAM28 is a serological and histochemical marker for non-small-cell lung cancers.
Int J Cancer. 2010 Oct 15 ;127(8):1844-56.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis.

Source

Abstract

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Full Text Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Cited by 12 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information